Foundry / Pipeline
Therapeutic pipeline.
Two oncology programs built around assets with prior human PK data. Explore their prior clinical development and Eigen’s current validation preparation.
Evidence reviewed
ONCOLOGY PRIOR CLINICAL DEVELOPMENT
- Prior development
- Phase reached
- Future development
Swipe to explore all development stages
| Program / indication | Research & preclinical | Development | Clinical studies | |||
|---|---|---|---|---|---|---|
| Discovery | Preclinical | Clinical preparation | Phase 1 | Phase 2 | Phase 3 | |
EG-01Prostate cancerTreatment-persistent prostate cancer.Human PK data available | Prior clinical development: Discovery | Prior clinical development: Preclinical | Prior clinical development: Clinical preparation | Phase 1 reached; prior clinical development | Future development: Phase 2 | Future development: Phase 3 |
Eigen indication work Asset evaluation & validation preparation | ||||||
EG-02Colorectal cancerTreatment-persistent colorectal cancer.Human PK data available | Prior clinical development: Discovery | Prior clinical development: Preclinical | Prior clinical development: Clinical preparation | Phase 1 reached; prior clinical development | Future development: Phase 2 | Future development: Phase 3 |
Eigen indication work Asset evaluation & validation preparation | ||||||
Bars show prior clinical development, with human PK data available. Endpoints mark the phase reached. Eigen’s current indication work appears beneath each bar. Future development remains subject to validation, rights and regulatory planning.
Bars show prior asset development reaching Phase 1. Eigen’s current work in the proposed indications is asset evaluation and validation preparation.
Future clinical plans will draw on existing human data, indication-specific validation, appropriate rights and regulatory review.
Candidate identities and detailed evidence can be discussed with prospective partners.